A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
Public ClinicalTrials.gov record NCT01209689. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Parallel Group Placebo-controlled Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab (TCZ) Versus Placebo in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous TNF Antagonist Therapy
Study identification
- NCT ID
- NCT01209689
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 113 participants
Conditions and interventions
Conditions
Interventions
- Tocilizumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2010
- Primary completion
- Nov 30, 2011
- Completion
- Nov 30, 2011
- Last update posted
- Jan 16, 2013
2010 – 2011
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntington Beach | California | 92646 | — |
| Not listed | Aventura | Florida | 33180 | — |
| Not listed | Miami | Florida | 33169 | — |
| Not listed | Orlando | Florida | 32804 | — |
| Not listed | Tampa | Florida | 33609 | — |
| Not listed | Atlanta | Georgia | 30342 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | Idaho Falls | Idaho | 83404 | — |
| Not listed | Wichita | Kansas | 67207 | — |
| Not listed | Hagerstown | Maryland | 21740 | — |
| Not listed | Saint Claire Shores | Michigan | 48081 | — |
| Not listed | Freehold | New Jersey | 07728 | — |
| Not listed | Asheville | North Carolina | 28803 | — |
| Not listed | Charlotte | North Carolina | 28210 | — |
| Not listed | Greensboro | North Carolina | 27408 | — |
| Not listed | Duncansville | Pennsylvania | 16635 | — |
| Not listed | Austin | Texas | 78731 | — |
| Not listed | Houston | Texas | 77004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 121 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01209689, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2013 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01209689 live on ClinicalTrials.gov.